dsdsa

product

Chinese Professional Rivaroxaban - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai

Short Description:


Product Detail

FAQ

Product Tags

Related Video

Feedback (2)

We can always satisfy our respected customers with our good quality, good price and good service due to we are more professional and more hard-working and do it in cost-effective way for Mesylate-Azd9291, 12650-69-0, Methotrexate Powder, We sincerely count on exchange and cooperation with you. Allow us to move ahead hand in hand and attain win-win situation.
Chinese Professional Rivaroxaban - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai Detail:

Product name Tofacitinib Citrate
Synonyms (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate; CP 690500-10; CP 690550-10; (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate
CAS No. 540737-29-9
Appearance Off white to white powder
Molecular Formula C16H20N6O.C6H8O7
Molecular Weight 504.50
Application Pharmaceutical grade or research purpose
Packing As per your request
Storage Preserve in tight,light-resistant containers in a cool place

 

Tofacitinib Citrate (CAS #540737-29-9)

ITEMS

STANDARDS

RESULTS

Appearance

Off white to white powder

Off white powder

Identification

HPLC; IR; HNMR

Complies

Solubility

Soluble in DMSO at 100mg/ml, very poorly soluble in ethanol, sparingly soluble in water etc.

Complies

Loss on Drying

≤0.5%

0.12%

Residue on ignition

≤0.1%

0.05%

Heavy metals

≤10ppm

Complies

Related Substances

Diastereomer (RS+SR) ≤0.1%

Single Impurity ≤0.15%

Total impurities ≤1.0%

0.05%

0.14%

0.18%

Enantiomorphism Isomers

≤0.2%

Complies

Residual Solvents

Ethanol ≤5000ppm

Methanol ≤3000ppm

Toluene ≤890ppm

Complies

Citrate Content

36.2%~40%

37.8%

Purity

≥99.0%

99.38%

Assay

60.68%~63.16% of Tofacitinib INN

98%~102% of Tofacitinib Citrate INN

62.04%

 

99.12%

Conclusion:Complies

Company Information

√ Management layer’s full experience in factory and skilled technicians followers;
√ Quality is always our top consideration, Strict QC system;
√ 11 years experienced exporting sales team;
√ Independent R&D lab;
√ Two signed long term GMP workshops;
√ Rich resources of plenty idle factories for customized project;
√ High Efficiency working team with consistent path.
imgsafSDGSHDASFG

Product detail pictures:

Chinese Professional Rivaroxaban - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

Chinese Professional Rivaroxaban - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

Chinese Professional Rivaroxaban - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures


Related Product Guide:

"Control the quality by the details, show the power by quality". Our enterprise has strived to establish a remarkably efficient and stable team team and explored an effective excellent control system for Chinese Professional Rivaroxaban - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai , The product will supply to all over the world, such as: Nairobi, UAE, Lithuania, Satisfaction and good credit to every customer is our priority. We focus on every detail of order processing for customers till they have received safe and sound solutions with good logistics service and economical cost. Depending on this, our solutions are sold very well in the countries in Africa, the Mid-East and Southeast Asia.
  • The sales person is professional and responsible, warm and polite, we had a pleasant conversation and no language barriers on communication.
    5 Stars By Jean Ascher from Benin - 2018.06.03 10:17
    This manufacturers not only respected our choice and requirements, but also gave us a lot of good suggestions, ultimately, we successfully completed the procurement tasks.
    5 Stars By Christine from Korea - 2017.08.16 13:39
    Write your message here and send it to us